- Conditions
- Type 2 Diabetes
- Interventions
- Insulin Glargine, Metformin, Prandial insulin, Exenatide
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 12
- States / cities
- San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 184
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide Once Weekly, Insulin Glargine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 12
- States / cities
- Escondido, California • Jacksonville, Florida • Orlando, Florida + 9 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide, Glipizide
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, Exenatide, Dapagliflozin, Exenatide and Dapagliflozin
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- AC2993, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 100
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Montgomery, Alabama + 82 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Exenatide once weekly suspension, Exenatide twice daily
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 58
- States / cities
- Muscle Shoals, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Exenatide-LAR plus Dapagliflozin placebo, Exenatide-LAR plus Dapagliflozin, Insulin Titration, Behavioral Therapy
- Drug · Behavioral
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Type 2 Diabetes
- Interventions
- Exenatide
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Cardiovascular Kidney Metabolic Syndrome
- Interventions
- Intervention, Active Comparator
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23,280,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- ITCA 650 Osmotic Mini Pump 20/60 mcg/day, ITCA 650 Osmotic Mini Pump 60 mcg/day, Metformin, Liraglutide
- Drug
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Little Rock, Arkansas + 28 more
- Conditions
- Childhood Obesity
- Interventions
- Family Based Behavioral Treatment, Exenatide 2 mg [Bydureon], Placebo
- Behavioral · Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 10 Years to 12 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Polycystic Ovary Syndrome, Obesity
- Interventions
- Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA, Dapagliflozin plus Glucophage (MET ER), Phentermine /Topiramate (PHEN/ TPM) ER
- Drug
- Lead sponsor
- Woman's
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 119 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Type 2 Diabetes
- Interventions
- ITCA 650 60 mcg/day, glimepiride
- Drug
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Hayward, California
- Conditions
- Diabetes Mellitus
- Interventions
- Exenatide, Exenatide matching placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 56 more
- Conditions
- Type 2 Diabetes
- Interventions
- BMS-686117, Byetta, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Knoxville, Tennessee
- Conditions
- Prediabetes, Obesity
- Interventions
- Exenatide, Saxagliptin, Exenatide extended-release (ER), Placebo
- Drug · Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 2 Diabetes
- Interventions
- Byetta (exenatide), Symlin (pramlintide)
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hypothalamic Obesity
- Interventions
- Exenatide, placebo
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Nashville, Tennessee • Seattle, Washington
- Conditions
- Obesity, Morbid
- Interventions
- Exenatide
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 8 Years to 19 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2944876, Exenatide extended-release, Placebo, Metformin
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 31
- States / cities
- Concord, California • Fresno, California • Los Angeles, California + 27 more
- Conditions
- Cardiovascular Events, Type2 Diabetes, Renal Disease
- Interventions
- SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 781,430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide SC, Exenatide IV, Placebo SC, Exendin-9, Placebo IV
- Drug
- Lead sponsor
- Carl T. Hayden VA Medical Center
- Federal
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- AC2993
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 219
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 162 more
- Conditions
- Type 2 Diabetes
- Interventions
- ITCA 650 (exenatide in DUROS)
- Drug
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 3
- States / cities
- Miami Gardens, Florida • Cincinnati, Ohio • San Antonio, Texas